Phase 1, open-label, dose-escalation study of sorafenib in combination with eribulin in patients with advanced, metastatic, or refractory solid tumors

Cancer Chemotherapy and Pharmacology
Frederik MarméJan Eucker

Abstract

Combining sorafenib and eribulin mesylate may provide synergistic antitumor activities with limited overlapping toxicities. This phase 1b, open-label, dose-escalation study evaluated safety, pharmacokinetics, maximum tolerated dose/recommended phase 2 dose (MTD/RP2D), and preliminary efficacy of sorafenib plus standard-dose eribulin mesylate in patients with advanced, metastatic, or refractory tumors. Patients received sorafenib 200 mg twice daily (BID; n = 5), 600 mg/day (n = 8), and 400 mg BID (MTD; n = 27). Dose-limiting toxicities were increased alanine aminotransferase and acute coronary syndrome (both grade 3) in the 400-mg BID dose-escalation and expansion cohorts, respectively. No significant increase in mean QTcF duration was observed with eribulin plus sorafenib versus eribulin alone; there were no drug-drug interactions. Five patients achieved partial response; 16 achieved stable disease. The combination of sorafenib and eribulin mesylate presented no unexpected safety concerns and no significant impact on QT/QTc intervals or drug-drug interactions. Sorafenib 400 mg BID plus standard-dose eribulin is the RP2D.

References

Nov 5, 1999·Oncology·M MaemuraY Morishita
Mar 2, 2006·Journal of the National Cancer Institute·Francesca CarlomagnoMassimo Santoro
Jan 12, 2007·The New England Journal of Medicine·Bernard EscudierUNKNOWN TARGET Study Group
Jul 25, 2008·The New England Journal of Medicine·Josep M LlovetUNKNOWN SHARP Investigators Study Group
Dec 3, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alvaro Moreno-AspitiaEdith A Perez
Jun 4, 2010·Cancer Chemotherapy and Pharmacology·Anthony W TolcherPavur R Sundaresan
Sep 25, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Maximilian MerzTobias Bäuerle
Mar 8, 2011·Lancet·Javier CortesUNKNOWN EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician's Choice Versus E7389) investigators
Aug 24, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Sarika Jain, Linda T Vahdat
May 24, 2012·Expert Opinion on Investigational Drugs·William J Gradishar
Dec 10, 2013·Breast Cancer Research and Treatment·E TilchG Chenevix Trench
Jan 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter A KaufmanJavier Cortes
Apr 4, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Nicholas F Dybdal-HargreavesSusan L Mooberry

❮ Previous
Next ❯

Citations

Aug 11, 2020·European Journal of Drug Metabolism and Pharmacokinetics·Agnieszka KarbownikEdyta Szałek
May 13, 2020·Cancer Chemotherapy and Pharmacology·Agnieszka KarbownikEdyta Szałek

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
F de BraudT De Pas
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Christopher J SweeneyHoward Burris
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
Igor PuzanovT R Jeffry Evans
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Otto SoepenbergA T van Oosterom
© 2022 Meta ULC. All rights reserved